Everence Capital Management Inc Catalyst Pharmaceuticals, Inc. Transaction History
Everence Capital Management Inc
- $1.59 Billion
- Q3 2024
A detailed history of Everence Capital Management Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Everence Capital Management Inc holds 15,260 shares of CPRX stock, worth $318,476. This represents 0.02% of its overall portfolio holdings.
Number of Shares
15,260
Previous 15,260
-0.0%
Holding current value
$318,476
Previous $230,000
31.74%
% of portfolio
0.02%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding CPRX
# of Institutions
326Shares Held
94MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$390 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$168 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$130 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$119 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$63 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.15B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...